Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr:68:169-171.
doi: 10.1016/j.jcrc.2021.11.001. Epub 2021 Nov 14.

Single-dose tocilizumab blunts systemic inflammation in severe COVID-19 patients

Charles de Roquetaillade  1 , Jérémie Guillemin  2 , Adrien Picod  3 , Alexandre Mebazaa  2 , Antoine Kimmoun  4 , Benjamin Glenn Chousterman  2 ; Toci-Covid investigators
Affiliations

Single-dose tocilizumab blunts systemic inflammation in severe COVID-19 patients

Charles de Roquetaillade et al. J Crit Care. 2022 Apr.
No abstract available

Keywords: COVID-19; IL-6; Immunotherapy; Tocilizumab.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest BC served as an advisory board member for Roche diagnostics. All other authors declare no conflict of interest with the present study. Dr. Mebazaa reports personal fees from Orion, Servier, Otsuka, Philips, Sanofi, Adrenomed, Epygon and Fire 1 and grants and personal fees from 4TEEN4, Abbott, Roche and Sphyngotec.

Figures

Fig. 1
Fig. 1
Kinetic analysis of immune parameters in COVID-19 patients within first week of admission according to tocilizumab administration. Time course of immune parameters following ICU-admission between Covid-19 patients who either received dexamethasone + tocilizumab (red) or dexamethasone alone (blue). For intergroup comparison, data were compared using the Mann-Whitney U tests only when interaction was significantly different between group (linear mixed model); CRP: C-reactive protein; PCT: Procalcitonin *p < 0.05.
See this image and copyright information in PMC

References

    1. https://files.covid19treatmentguidelines.nih.gov/guidelines/covid19treat...
    1. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA. 2021;326(6):499–518. doi: 10.1001/JAMA.2021.11330. - DOI - PMC - PubMed
    1. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19New Engl J Med. 2021;384:1491–1502. - PMC - PubMed
    1. Abani O., Abbas A., Abbas F., Abbas M., Abbasi S., Abbass H., et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2021;397:1637–1645. doi: 10.1016/S0140-6736(21)00676-0. - DOI - PMC - PubMed
    1. Salama C., Han J., Yau L., et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. New Engl J Med. 2021;384:20–30. - PMC - PubMed

MeSH terms

Substances